A retired medical director recounted direct operational problems that accompanied Theranos’ rollout in Phoenix. He wrote that Theranos’ single-drop, finger-stick approach produced too little blood for repeat or reflex testing — an important deficiency because routine venipuncture yields several milliliters of serum or plasma that laboratories store and re-test without recalling patients. He noted fingerprint sticks are often more painful than venipuncture. The reader added that local physicians voiced frustration to the receiving laboratory over these shortcomings. The letter also argued that Theranos’ business model — enabling easy access to self-directed testing — clashes with the realities of an insurance-based system in which payers require diagnosis codes supplied by a licensed clinician. The author concluded that even if Theranos’ instruments had worked, the economic model may have been incompatible with mainstream laboratory integration. The original report did not provide trial data or technical performance parameters for the devices; the letter focuses on workflow and reimbursement mismatches observed in practice.
Several readers commented on Tyler Shultz’s essay and on a new documentary about Elizabeth Holmes. One correspondent who described themselves as a documentary filmmaker reflected on editorial decisions, suggesting that filmmakers sometimes sympathize with their subjects during the edit and that structural choices can alter audience perception. Another reader, who lived through the Theranos episode, emphasized the personal harm caused by Holmes’ actions and expressed frustration that a film might not foreground her crimes. A separate letter argued the documentary examines deceit as an object of study and raises questions about how a person capable of large-scale fraud develops. These reactions illustrate differing expectations among survivors, journalists, and artists about how investigative narratives should balance legal culpability, psychological profiling, and cinematic exploration.
In response to an essay on nonadherence, a patient who had undergone a mitral valve replacement described the psychological struggle that accompanies lifelong pharmacotherapy. The reader agreed that patients sometimes avoid prolonged medication use not from ignorance or lack of funds but because continuous therapy can feel like a loss of identity — an existential shift that clinicians may underrecognize. They urged clinicians to incorporate conversations about identity, control, and psychological adaptation when counseling patients about long-term regimens. The letter did not report specific adherence rates or interventions; it offered lived experience as a clinical prompt for more empathetic counseling.
A critical letter addressed claims about integrative oncology, distinguishing mainstream supportive measures from what the correspondent called “biofield” therapies. The reader noted that professional guidelines cited in support of integrative approaches include interventions such as exercise, medical massage, biofeedback, and yoga — therapies with measurable outcomes and guideline backing. By contrast, the correspondent argued that energy-based therapies (referred to as biofield therapy) lack reproducible demonstration of an underlying physical phenomenon. They cited prior research in which therapeutic-touch practitioners could not detect the energy field they claim to manipulate, performing at chance levels in controlled tests. The letter also disputed an assertion that the Department of Veterans Affairs includes reiki and similar modalities in its integrative offerings, saying that the VA link provided in the original essay did not mention those therapies. The correspondent framed research into unestablished phenomena as premature unless the phenomenon itself is first demonstrated under controlled conditions.
Several readers responded to H. Gilbert Welch’s critique of the Galleri multi-cancer screening test. They echoed his concern that the test misses a large proportion of early-stage cancers in the company’s studies: stage 1 cancers were reportedly missed in the majority of cases in the cited data, and stage 2 cancers were missed in roughly two-thirds of cases in at least one study. Detection rates for late-stage disease were also imperfect. Readers argued these performance characteristics do not constitute evidence of a screening test that detects cancers early enough to reduce mortality. They warned of two categories of potential harm. First, false reassurance from a negative test could delay patients from seeking care when symptoms appear, producing diagnostic delays that might be clinically consequential. Second, positive results can trigger invasive follow-up: the letters stated that many patients who received a Galleri signal underwent biopsies, endoscopies, or surgery, and that the median time to being told they did not have cancer was prolonged (one letter cited a median wait of 75 days). Readers worried that mass use of such a test would increase demand for specialist evaluation and diagnostic procedures, lengthening waits for both those with positive screening signals and people who already have symptoms and need timely diagnostic workup.
Across these letters, readers consistently emphasized unresolved questions that the published essays and source data did not settle. They asked whether multi-cancer screening with the Galleri platform ultimately reduces cancer-specific or all-cause mortality — data the letters noted are not established in the material cited. They questioned how follow-up capacity would be scaled if millions of people used such screening, and whether extended waits for diagnostic clarification might offset potential benefits of earlier detection. On integrative oncology, readers requested clearer separation between modalities supported by clinical guidelines and those resting on unproven mechanisms. And regarding Theranos, correspondents pressed the practical disconnect between a single-drop, consumer-directed testing model and laboratory workflows and reimbursement requirements in standard medical practice. These are concrete gaps in evidence and system planning that the letters identify as priorities for clinicians, policymakers, and researchers to address.